- $93.25m
- $145.13m
- $149.16m
Neuronetics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Neuronetics Reports Record Fourth Quarter And Record Full Year 2022 Financial And Operating Results
Neuronetics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Neuronetics Announces Tms Coverage Criteria Changes For Over 23 Million Covered Lives
Neuronetics rises on supply deal with Greenbrook
Brief: Neuronetics And Greenbrook TMS Announce Six Year Exclusive Partnership
Brief: Neuronetics Announces Data Confirming Efficacy In Treating Anxious Depression With NeuroStar Advanced Therapy For Mental Health
Brief: Neuronetics Settles Litigation Against Brainsway
Brief: Neuronetics Says Preliminary Unaudited Total Revenue For Q4 Of 2022 Is About $18.0 Million
Neuronetics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Neuronetics Reports Third Quarter 2022 Results
Neuronetics Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Neuronetics Announces 510(K) Clearance Of D-Tect MT Accessory For Neurostar Advanced Therapy For Mental Health
Brief: Neuronetics Inc - Bruce J. Shook Notified Board Of His Decision To Resign From Board Effective As Of October 31, 2022
Brief: Neuronetics Files For $125 Million Mixed Shelf Offering
Neuronetics rises on Q2 revenue beat, forecast raise
Brief: Neuronetics Inc Posts Q2 Revenue Of $16.3 Mln
Neuronetics Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Neuronetics And Alleviant Health Centers Announce Exclusive Partnership